Michael Shinall is a Principal at Choate, Hall & Stewart LLP. Michael Shinall, using his industry and research experience in the fields of chemistry and pharmaceuticals, works with clients to develop strategies to protect their technology and business assets. His practice focuses on patent portfolio management, post-grant proceedings, and licensing/transactional agreements.
During his time at Choate, Michael has assisted a wide variety of clients, big and small, from maintaining worldwide patent coverage for approved small molecule therapeutics, to establishing foundational IP to build value for a new company. Michael also counsels clients on lifecycle management of their critical programs, and works with clients to identify creative solutions to protect their valuable assets.
Michael also advises clients on contentious matters in the United States (including inter partes review and post-grant review proceedings), as well as extensions of those proceedings outside the U.S., such as third-party observations in Europe.
Michael’s clients include Olema Oncology, Casma Therapeutics, BioNTech SE, and Saudi Arabian Oil Company.
Check back soon for more articles by Michael Shinall